

David Martn-Garca

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/636435/david-martin-garcia-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98 papers	3,722 citations	29 h-index	60 g-index
109 ext. papers	4,486 ext. citations	4.5 avg, IF	4.17 L-index

#	Paper	IF	Citations
98	Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102321	2.2	4
97	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. <i>Cancers</i> , 2022 , 14, 2673	6.6	0
96	Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). <i>Blood</i> , 2021 , 138, 430-430	2.2	0
95	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2021 , JCO2101815	2.2	10
94	EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and S2ary syndrome: real-world data in Spanish patients (MICADOS study). <i>European Journal of Cancer</i> , 2021 , 156 Suppl 1, S29-S30	7.5	
93	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1919-1928	4.4	1
92	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. <i>Cancer Medicine</i> , 2021 , 10, 3214-3223	4.8	9
91	Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial 2021 , 9,		6
90	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping. <i>British Journal of Haematology</i> , 2021 , 195, 542-551	4.5	1
89	Genetic complexity impacts the clinical outcome of follicular lymphoma patients. <i>Blood Cancer Journal</i> , 2021 , 11, 11	7	0
88	R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients 80 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. <i>Cancer Medicine</i> , 2021 , 10, 1314-1326	4.8	5
87	A randomized phase II study comparing consolidation with a single dose of Y ibritumomab tiuxetan maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. <i>Leukemia and Lymphoma</i> , 2021 , 1-8	1.9	1
86	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021 , 5, 2965-2968	7.8	0
85	translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival. <i>Leukemia and Lymphoma</i> , 2021 , 1-8	1.9	1
84	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. <i>Blood</i> , 2020 , 135, 996-1007	2.2	32
83	Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. <i>Journal of Neuro-Oncology</i> , 2020 , 148, 545-554	4.8	7
82	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. <i>Blood</i> , 2020 , 136, 1419-1432	2.2	53

81	Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2020 , 12,	6.6	4
80	RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. <i>Annals of Hematology</i> , 2020 , 99, 799-808	3	10
79	Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8019-8019	2.2	1
78	Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units. <i>European Journal of Dermatology</i> , 2020 , 30, 397-403	0.8	
77	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020 , 104, 400-408	3.8	1
76	New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). <i>British Journal of Haematology</i> , 2020 , 188, 666-667	4.5	13
75	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. <i>Blood Cancer Journal</i> , 2019 , 9, 52	7	4
74	Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 809-824	11.5	31
73	Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. <i>British Journal of Haematology</i> , 2019 , 185, 480-491	4.5	14
72	Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019 , 12, 194-203	2.7	3
71	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2815-2824	2.2	93
70	Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. <i>Cancer Medicine</i> , 2019 , 8, 6855-6866	4.8	3
69	Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. <i>British Journal of Haematology</i> , 2019 , 184, 797-807	4.5	5
68	A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group. <i>American Journal of Hematology</i> , 2018 , 93, 867-873	7.1	11
67	Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. <i>Bone Marrow Transplantation</i> , 2018 , 53, 780-783	4.4	5
66	A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. <i>Modern Pathology</i> , 2018 , 31, 732-743	9.8	23
65	Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm. <i>British Journal of Haematology</i> , 2018 , 182, 534-541	4.5	7
64	Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. <i>Hematological Oncology</i> , 2018 , 36, 765-772	1.3	13

63	Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018 , 9, 32383-32399	3.3	6
62	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 379, 934-947	59.2	168
61	A novel mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. <i>Blood Advances</i> , 2018 , 2, 2959-2963	7.8	8
60	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018 , 132, 413-422	2.2	58
59	Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β_2 -microglobulin yields a more accurate GELTAMO-IPI. <i>British Journal of Haematology</i> , 2017 , 176, 918-928	4.5	50
58	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. <i>Hematological Oncology</i> , 2017 , 35, 520-527	1.3	15
57	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. <i>Haematologica</i> , 2017 , 102, e360-e363	6.6	17
56	Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1631-1640	4.7	22
55	Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). <i>Haematologica</i> , 2017 , 102, 235-245	6.6	29
54	Plitidepsin: design, development, and potential place in therapy. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 253-264	4.4	46
53	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2900-2910	2.2	175
52	F-FDG PET/CT in the clinical management of patients with lymphoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2017 , 36, 312-321	0.4	2
51	Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. <i>British Journal of Haematology</i> , 2017 , 178, 699-708	4.5	42
50	Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma. <i>Cancer Medicine</i> , 2017 , 6, 2766-2774	4.8	9
49	Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2017 , 6, 2507-2514	4.8	7
48	Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). <i>Annals of Hematology</i> , 2017 , 96, 1323-1330	3	2
47	The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1144-1152	1.9	16
46	Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine \pm Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 53-59	4.7	6

45	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). <i>Histopathology</i> , 2017 , 70, 595-621	7.3	32
44	MYC rearrangement in aggressive B-cell lymphomas: A major therapeutic challenge. <i>Medicina Clínica (English Edition)</i> , 2017 , 149, 343-344	0.3	
43	Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era. <i>Blood</i> , 2017 , 130, 827-827	2.2	1
42	Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 1517-1527	3.8	15
41	High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016 , 95, 253-62	3	14
40	Lymphoma Heterogeneity: Three Different Histological Pictures and One Unique Clone. <i>Case Reports in Hematology</i> , 2016 , 2016, 3947510	0.7	3
39	Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. <i>British Journal of Haematology</i> , 2016 , 173, 245-52	4.5	16
38	Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?. <i>Annals of Hematology</i> , 2015 , 94, 609-16	3	7
37	Cutaneous annular lesions as the first sign of transformation of follicular lymphoma into diffuse large B-cell lymphoma. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2015 , 81, 495-7	0.8	5
36	Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. <i>British Journal of Haematology</i> , 2014 , 164, 668-74	4.5	14
35	Diagnostic utility of bone marrow examination for the assessment of patients with fever of unknown origin: a 10-year single-centre experience. <i>Internal Medicine Journal</i> , 2014 , 44, 610-2	1.6	8
34	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. <i>Haematologica</i> , 2014 , 99, e138-41	6.6	2
33	Multiparameter flow cytometry for the identification of the Waldenström clone in IgM-MGUS and Waldenström Macroglobulinemia: new criteria for differential diagnosis and risk stratification. <i>Leukemia</i> , 2014 , 28, 166-73	10.7	57
32	Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. <i>British Journal of Haematology</i> , 2014 , 167, 327-36	4.5	31
31	Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. <i>Blood</i> , 2014 , 124, 1677-1677	2.2	1
30	Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. <i>Annals of Hematology</i> , 2013 , 92, 1151-79	3	18
29	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 122, 1448-54	2.2	18
28	First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. <i>Haematologica</i> , 2013 , 98, 1563-70	6.6	21

27	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012 , 119, 687-91	2.2	225
26	Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005. <i>American Journal of Pathology</i> , 2012 , 181, 1870-8	5.8	20
25	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. <i>Leukemia</i> , 2012 , 26, 1862-9	10.7	54
24	Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. <i>American Journal of Pathology</i> , 2012 , 181, 1879-88	5.8	24
23	Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 168-71	2	12
22	Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1627-33	2.2	178
21	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. <i>Blood</i> , 2011 , 118, 4547-53	2.2	52
20	Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. <i>Leukemia</i> , 2011 , 25, 697-706	10.7	60
19	Risk of progression in smoldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. <i>British Journal of Haematology</i> , 2010 , 148, 110-4	4.5	82
18	Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2010 , 21, 1891-1897	10.3	12
17	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. <i>Lancet Oncology</i> , 2010 , 11, 934-41	21.7	384
16	The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. <i>Blood</i> , 2009 , 114, 4369-72	2.2	56
15	R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome. <i>Haematologica</i> , 2009 , 94, 744	6.6	5
14	Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. <i>Haematologica</i> , 2009 , 94, 1771-5	6.6	55
13	R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. <i>Haematologica</i> , 2008 , 93, 1829-36	6.6	139
12	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. <i>Blood</i> , 2008 , 112, 4017-23	2.2	370
11	New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. <i>Blood</i> , 2007 , 110, 2586-92	2.2	365
10	Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers. <i>Cytotherapy</i> , 2007 , 9, 14-22	4.8	24

9	Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too. <i>British Journal of Haematology</i> , 2006 , 134, 645-6	4.5	1
8	Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma. <i>Bone Marrow Transplantation</i> , 2004 , 33, 579-87	4.4	5
7	Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. <i>Bone Marrow Transplantation</i> , 2004 , 34, 675-82	4.4	7
6	Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities. <i>Leukemia Research</i> , 2004 , 28, 1181-7	2.7	8
5	Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. <i>Blood</i> , 2003 , 102, 2994-3002	2.2	83
4	Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. <i>British Journal of Haematology</i> , 2002 , 118, 239-42	4.5	47
3	Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. <i>British Journal of Haematology</i> , 2001 , 113, 161-71	4.5	71
2	Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. <i>Bone Marrow Transplantation</i> , 1999 , 23, 997-1002	4.4	14
1	Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 24, 1279-83	4.4	52